Hutchison China Meditech Ltd., of London, said intends to offer $262 million of American Depositary Shares (ADSs), each representing one-half of one ordinary share, par value $1 each of Chi-Med on the Nasdaq Global Select Market. The company intends to grant the underwriters a 30-day option to purchase up to $39.3 million of additional ADSs at the offering price. The proceeds from the offering, if completed, are expected to be used to fund the on-going research and development of the Chi-Med innovation platform drug pipeline and for working capital and general corporate purposes.